Natera Launches Proposed Follow-On Offering
06 Setembro 2023 - 5:24PM
Business Wire
Natera, Inc. (Nasdaq: NTRA) (“Natera”), a global leader in
cell-free DNA (cfDNA) testing, today announced the launch of a
proposed follow-on public offering of $250,000,000 of shares of its
common stock. In addition, Natera expects to grant the underwriters
a 30-day option to purchase up to an additional $37,500,000 of
shares of its common stock at the public offering price less the
underwriting discounts and commissions. The offering is subject to
market and other conditions.
Morgan Stanley, Goldman Sachs & Co. LLC, TD Cowen and Piper
Sandler are acting as joint book-running managers for the
offering.
The securities described above are being offered pursuant to an
automatically effective shelf registration statement on Form S-3
that was filed with the U.S. Securities and Exchange Commission
(the “SEC”) on September 6, 2023, including a preliminary
prospectus. When available, copies of the preliminary prospectus
may be obtained by contacting Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014; Goldman Sachs & Co. LLC, 200 West Street, New
York, NY 10282, Attention: Prospectus Department, by telephone at
(866) 471-2526 or by emailing Prospectus-ny@ny.email.gs.com; Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by
email at Prospectus_ECM@cowen.com or by telephone at (833)
297-2926; or Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by
telephone at (800) 333-6000, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated
to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard
of care to protect health, and enable earlier, more targeted
interventions that help lead to longer, healthier lives. Natera’s
tests are validated by more than 150 peer-reviewed publications
that demonstrate high accuracy. Natera operates ISO 13485-certified
and CAP-accredited laboratories certified under the Clinical
Laboratory Improvement Amendments (CLIA) in Austin, Texas and San
Carlos, California.
Forward-looking Statements
Except for historical information, certain statements in this
press release, including statements regarding the proposed
follow-on public offering and the proposed terms of such offering,
are forward-looking in nature and are subject to risks,
uncertainties and assumptions about Natera and its business,
including, without limitation, risks and uncertainties related to
market conditions and whether the proposed offering will be
completed on the expected terms or at all. Such forward-looking
statements involve substantial risks and uncertainties that relate
to future events and the actual results could differ significantly
from those expressed or implied by the forward-looking statements.
Any forward-looking statements are based on Natera’s current
expectations, estimates and assumptions regarding future events and
are applicable only as of the dates of such statements. Natera
makes no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances that may
change, except as required by law. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Natera’s business in general, please refer to
the “Risk Factors” section in Natera’s automatically effective
shelf registration statement on Form S-3 filed with SEC on
September 6, 2023 and the documents incorporated by reference
therein, including its Annual Report on Form 10-K filed with the
SEC on March 1, 2023 and its Quarterly Reports on Form 10-Q filed
with the SEC on May 10, 2023, and August 4, 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906591286/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera,
Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Natera (NASDAQ:NTRA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024